JP2018516936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516936A5 JP2018516936A5 JP2017562987A JP2017562987A JP2018516936A5 JP 2018516936 A5 JP2018516936 A5 JP 2018516936A5 JP 2017562987 A JP2017562987 A JP 2017562987A JP 2017562987 A JP2017562987 A JP 2017562987A JP 2018516936 A5 JP2018516936 A5 JP 2018516936A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- active agent
- cancer
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013543 active substance Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 claims 8
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 claims 8
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 claims 8
- 229960005552 PAC-1 Drugs 0.000 claims 8
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 6
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 229960002465 dabrafenib Drugs 0.000 claims 5
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 5
- 229960003862 vemurafenib Drugs 0.000 claims 5
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical group CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 5
- 208000025127 Erdheim-Chester disease Diseases 0.000 claims 4
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 claims 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- -1 PLX3603 Chemical compound 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950001969 encorafenib Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171882P | 2015-06-05 | 2015-06-05 | |
| US62/171,882 | 2015-06-05 | ||
| US201662345629P | 2016-06-03 | 2016-06-03 | |
| US62/345,629 | 2016-06-03 | ||
| PCT/US2016/036063 WO2016197129A1 (en) | 2015-06-05 | 2016-06-06 | Pac-1 combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018516936A JP2018516936A (ja) | 2018-06-28 |
| JP2018516936A5 true JP2018516936A5 (enExample) | 2019-06-20 |
| JP7033451B2 JP7033451B2 (ja) | 2022-03-10 |
Family
ID=57442182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562987A Active JP7033451B2 (ja) | 2015-06-05 | 2016-06-06 | Ｐａｃ－１併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10350207B2 (enExample) |
| EP (1) | EP3302478B1 (enExample) |
| JP (1) | JP7033451B2 (enExample) |
| KR (1) | KR102656027B1 (enExample) |
| CN (2) | CN108135896A (enExample) |
| AU (1) | AU2016271527B2 (enExample) |
| BR (1) | BR112017026140A2 (enExample) |
| CA (1) | CA2987340C (enExample) |
| DK (1) | DK3302478T3 (enExample) |
| ES (1) | ES2906763T3 (enExample) |
| IL (1) | IL256111B2 (enExample) |
| MX (1) | MX380835B (enExample) |
| RU (1) | RU2720509C2 (enExample) |
| WO (1) | WO2016197129A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365392B (es) * | 2012-03-06 | 2019-05-31 | Univ Illinois | Composición de combinación de pac-1 y doxorrubicina. |
| WO2016197129A1 (en) * | 2015-06-05 | 2016-12-08 | The Board Of Trustees Of The University Of Illinois | Pac-1 combination therapy |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2018368453B2 (en) * | 2017-11-17 | 2024-05-30 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual MEK signaling |
| KR20210084442A (ko) * | 2018-10-05 | 2021-07-07 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 포도막 흑색종 치료를 위한 병용 요법 |
| MX2021014758A (es) * | 2019-05-30 | 2022-03-11 | Univ Illinois | Activación e inmunoterapia de procaspasa-3 para el tratamiento de cáncer. |
| US20230355581A1 (en) * | 2020-07-02 | 2023-11-09 | The Board of Regents of the Unversity of Texas System | Methods of treatment for melanoma |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| FR2757866B1 (fr) | 1996-12-30 | 2004-12-17 | Catalyse | Polymeres comportant des groupes ammoniums quaternaires, leur utilisation pour la fabrication d'un materiau a propretes antibacteriennes et leurs procedes de preparation |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US20070049602A1 (en) | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| WO2010091382A1 (en) | 2009-02-09 | 2010-08-12 | The Board Of Trustees Of The University Of Illinois | Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| AU2010210404A1 (en) * | 2009-02-09 | 2011-08-25 | St. Jude Medical, Cardiology Division, Inc. | Inflatable minimally invasive system for delivering and securing an annular implant |
| US20140348819A1 (en) | 2011-06-24 | 2014-11-27 | Dana-Farber Cancer Institute, Inc. | Methods of Treating Cancer |
| US8916705B2 (en) | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
| EP2819661B1 (en) | 2012-03-02 | 2016-11-09 | The Board of Trustees of the University of Illionis | Potent anticancer activity via dual compound activation |
| US20130228486A1 (en) * | 2012-03-05 | 2013-09-05 | Ronald Mark Buck | Top mounting bottle container |
| JP6222608B2 (ja) | 2012-03-06 | 2017-11-01 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ | 膠芽腫のためのプロカスパーゼ併用療法 |
| MX365392B (es) | 2012-03-06 | 2019-05-31 | Univ Illinois | Composición de combinación de pac-1 y doxorrubicina. |
| US9249116B2 (en) | 2012-08-03 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
| US10201556B2 (en) * | 2012-11-06 | 2019-02-12 | Interna Technologies B.V. | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway |
| EP2964028A4 (en) * | 2013-03-05 | 2017-06-07 | University of Tennessee Research Foundation | Compounds for treatment of cancer |
| WO2014193898A1 (en) | 2013-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Combination therapies for cancer |
| TWI839690B (zh) | 2013-07-12 | 2024-04-21 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合的用途 |
| WO2016197129A1 (en) * | 2015-06-05 | 2016-12-08 | The Board Of Trustees Of The University Of Illinois | Pac-1 combination therapy |
-
2016
- 2016-06-06 WO PCT/US2016/036063 patent/WO2016197129A1/en not_active Ceased
- 2016-06-06 BR BR112017026140-5A patent/BR112017026140A2/pt not_active Application Discontinuation
- 2016-06-06 IL IL256111A patent/IL256111B2/en unknown
- 2016-06-06 CA CA2987340A patent/CA2987340C/en active Active
- 2016-06-06 JP JP2017562987A patent/JP7033451B2/ja active Active
- 2016-06-06 DK DK16804655.5T patent/DK3302478T3/da active
- 2016-06-06 CN CN201680045123.4A patent/CN108135896A/zh active Pending
- 2016-06-06 CN CN202311252422.3A patent/CN117257802A/zh active Pending
- 2016-06-06 MX MX2017015532A patent/MX380835B/es unknown
- 2016-06-06 AU AU2016271527A patent/AU2016271527B2/en active Active
- 2016-06-06 KR KR1020187000157A patent/KR102656027B1/ko active Active
- 2016-06-06 ES ES16804655T patent/ES2906763T3/es active Active
- 2016-06-06 EP EP16804655.5A patent/EP3302478B1/en active Active
- 2016-06-06 US US15/579,689 patent/US10350207B2/en active Active
- 2016-06-06 RU RU2017146346A patent/RU2720509C2/ru active
-
2019
- 2019-06-10 US US16/436,542 patent/US11129830B2/en active Active
-
2021
- 2021-09-28 US US17/487,473 patent/US12336992B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018516936A5 (enExample) | ||
| EP3515446B1 (en) | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor | |
| JP2024133475A5 (enExample) | ||
| JP7445893B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| JP6911047B2 (ja) | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| Monk et al. | A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer | |
| Bjørn et al. | Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera | |
| US10314834B2 (en) | Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| JP2018528206A (ja) | Ｍｄｍ２阻害剤およびその組み合わせ物 | |
| JP2019532051A5 (enExample) | ||
| JP2014525454A5 (enExample) | ||
| JP2018508516A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| RU2017146346A (ru) | Комбинированная терапия pac-1 | |
| JP2017513908A5 (enExample) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| JP2020536965A5 (enExample) | ||
| JP2020117553A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| RU2017119066A (ru) | Композии апилимода и способы их применения в лечении колоректального рака | |
| JP2014144962A5 (enExample) | ||
| JP2017533963A5 (enExample) | ||
| JP2015517523A5 (enExample) |